High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib

European Journal of Cancer

Volumn 50, Issue 7, 2014, Pages 1399-1401

  Kuiper, J L ^a   Heideman, D A M ^a   Thunnissen, E ^a   Van Wijk, A W ^a   Postmus, P E ^a   Smit, E F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

CANCER PATIENT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GENE MUTATION; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; HUMANS; LUNG NEOPLASMS; MENINGEAL NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84897397944     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.02.005     Document Type: Letter

References (11)

1. H.A. Yu, M.E. Arcila, N. Rekhtman, C.S. Sima, M.F. Zakowski, and W. Pao et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers Clin Cancer Res 19 8 2013 2240 2247
2. D.T. Milton, C.G. Azzoli, R.T. Heelan, E. Venkatraman, J.E. Gomez, and M.G. Kris et al. A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer Cancer 107 5 2006 1034 1041
3. J.L. Clarke, W. Pao, N. Wu, V.A. Miller, and A.B. Lassman High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer J Neurooncol 99 2 2010 283 286
4. C. Grommes, G.R. Oxnard, M.G. Kris, V.A. Miller, W. Pao, and A.I. Holodny et al. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer Neuro-oncol 13 12 2011 1364 1369
5. A. Hata, R. Kaji, S. Fujita, and N. Katakami High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer J Thorac Oncol 6 3 2011 653 654
6. D.M. Jackman, A.J. Holmes, N. Lindeman, P.Y. Wen, S. Kesari, and A.M. Borras et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib J Clin Oncol 24 27 2006 4517 4520
7. Y. Togashi, K. Masago, M. Fukudo, Y. Tsuchido, C. Okuda, and Y.H. Kim et al. Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation Cancer Chemother Pharmacol 68 4 2011 1089 1092
8. J.L. Kuiper, and E.F. Smit High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases-One with a remarkable thoracic response as well Lung Cancer 80 1 2013 102 105
9. C.D. Blanke, C. Rankin, G.D. Demetri, C.W. Ryan, M.M. von, and R.S. Benjamin et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 J Clin Oncol 26 4 2008 626 632
10. H.M. Kantarjian, M. Talpaz, S. O'Brien, F. Giles, G. Garcia-Manero, and S. Faderl et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia Blood 101 2 2003 473 475
11. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 1989 1 10